Completed PHASE1 INTERVENTIONAL 5-arm NCT03317717

Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

Phase 1 Study to Determine the Pharmacodynamic and Safety of MEDITOXIN®(Clostridium Botulinum Toxin Type A) in Healthy Male Volunteers

Sponsor: Medy-Tox

Conditions Healthy

Interventions Botox Meditoxin

Updated 6 times since 2017 Last updated: Mar 25, 2019 Started: Oct 12, 2017 Primary completion: Jan 30, 2018 Completion: Jan 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03317717, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Medy-Tox, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Nov 2017 — Apr 2019 [monthly]

Recruiting PHASE1

First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medy-Tox

Data source: Medy-Tox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea